Figure 4.

Effects of antisense S‐ODN and siRNA for receptor for advanced glycation end products (RAGE) and high mobility group box‐1 (HMGB1) and hrHMGB1 on melanoma inhibitory activity (MIA) expression in HSC3 human oral squamous cell carcinoma (OSCC) cells. (a) MIA expression was examined by immunoblotting in HSC3 human OSCC cells treated with antisense (AS) or sense (S) S‐ODN for RAGE and HMGB1 and human recombinant HMGB1 (hrHMGB1). Tubulin was served as a loading control. (b, c) MIA expression was examined by reverse transcriptase–polymerase chain reaction in HSC3 cells with or without treatment with siRNA for RAGE and HMGB1 or control siRNA. β‐actin was served as a loading control.